In an exploratory analysis evaluating the overall survival of patients with HR+/HER2+ advanced breast cancer (ABC) treated with CDK4/6 inhibitors, PALOMA-3, patients without TP53/PIK3CA/ESR2 mutations in ctDNA showed better overall survival and progression-free survival when treated with palbociclib plus fulvestrant, indicating that a driver gene mutation in ctDNA can support the predictive value for clinical medical management [133]. The gene discussed is ERBB2; the disease is breast carcinoma.